X

Drug Profile

XmAb TL1A x IL-23 bispecific antibody - Xencor

Alternative Names: TL1A x IL-23 bispecific antibody - Xencor

Latest Information Update: 03 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xencor
Class Anti-inflammatories; Bispecific antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Autoimmune disorders; Inflammation

Most Recent Events

09 Sep 2024 Early research in Autoimmune disorders in USA (Parenteral)
09 Sep 2024 Early research in Inflammation in USA (Parenteral)
09 Sep 2024 Xencor plans a first-in-human clinical trial for Autoimmune disorders and Inflammation (Parenteral), in 2026

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com